877402-24-9Relevant academic research and scientific papers
Microwave enhanced cross-coupling reactions involving alkenyl- and alkynyltrifluoroborates
Kabalka, George W.,Al-Masum, Mohammad,Mereddy, Arjun R.,Dadush, Eric
, p. 1133 - 1136 (2006)
Cross-coupling reactions of potassium arylvinyltrifluoroborates with aryl iodides in the presence of a palladium catalyst occur rapidly utilizing microwave irradiation. The coupled products are produced in excellent yields. Alkynyltrifluoroborates also undergo the coupling reaction.
Drug for treating depression
-
Paragraph 0028; 0032; 0033; 0034, (2018/10/19)
The invention discloses a drug for treating depression. The formula is as shown in the specification, wherein R1, R2 and R3 are independently selected from H, F or OCH3. In recent years, 5-serotonin 1A receptor partly excited and selective 5-serotonin reuptake inhibition of the dual role of antidepressants become a hot research focus of novel antidepressants. (H) 5-HT uptake inhibition experiment and h5-HT1A binding affinity experiment in rat synapse show that the compound has 5-HT reuptake inhibition and activating effect on 5-HT1A receptors, and the compound can serve as the drug for treating human central nervous system dysfunction like depression and anxiety.
A medicament for the treatment of depression (by machine translation)
-
Paragraph 0027; 0031; 0032; 0033, (2018/10/19)
The invention discloses a method for treating depression, Wherein: R1 , R2 , R3 , R4 Independently selected from the group of H, or CH F3 . In recent years, 5 - hydroxytryptamine 1 A receptor partial agonistic and selective 5 - hydroxytryptamine reuptake inhibition with dual function of antidepressant has become anti-depression pharmaceutical research and in the direction of the hot spots. In the RAT synapsis body to [3 H] 5 - HT uptake inhibition experiment and h5 - HT1 A In the experiment confirmed that the binding affinity of the compounds of the invention have 5 - HT reuptake inhibiting effect and to 5 - HT1 A Receptor agonistic, note the compounds of this invention can be used as treatment of human central nervous system dysfunction such as depression, anxiety neurosis. (by machine translation)
A medicament for the treatment of depression (by machine translation)
-
Paragraph 0028; 0032; 0033; 0034, (2018/10/19)
The invention discloses a method for treating depression, Wherein: R1 , R2 , R3 , R4 Independently selected from the group of H, F or OH. In recent years, 5 - hydroxytryptamine 1 A receptor partial agonistic and selective 5 - hydroxytryptamine reuptake inhibition with dual function of antidepressant has become anti-depression pharmaceutical research and in the direction of the hot spots. In the RAT synapsis body to [3 H] 5 - HT uptake inhibition experiment and h5 - HT1 A In the experiment confirmed that the binding affinity of the compounds of the invention have 5 - HT reuptake inhibiting effect and to 5 - HT1 A Receptor agonistic, note the compounds of this invention can be used as treatment of human central nervous system dysfunction such as depression, anxiety neurosis. (by machine translation)
Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists
Motoshima, Kazunori,Sugita, Kazuyuki,Hashimoto, Yuichi,Ishikawa, Minoru
, p. 3041 - 3045 (2011/06/24)
Novel dipeptidyl peptidase IV (DPP-IV) inhibitors with a phenethylphenylphthalimide skeleton were prepared based on α-glucosidase inhibitors and liver X receptor (LXR) antagonists derived from thalidomide. Representative compounds showed non-competitive i
